Overall, these data point to distinct epigenetic mechanisms of dysregulation of key prostate cancer biomarkers (GSTP1) including NE (ASCL1, SEZ6L), and luminal (e.g FOLH1) genes. This evidence concerns the gene ASCL1 and prostate cancer.